← Back to Directory

Icosapent Ethyl

Vascepa, purified EPA

Visual ViewRaw DataInteraction Data

Meta Information

ID:icosapent-ethyl
Name:Icosapent Ethyl
Schema Version:1.5

Alternate Names

  • Vascepa
  • purified EPA

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:
50
High Cost:
350
Cost Type:
monthly
Description:
Prescription cost; often covered by insurance for specific cardiovascular risk factors.

Summary

Icosapent ethyl, a prescription-grade form of the omega-3 fatty acid EPA, is primarily used in high-risk individuals to lower triglycerides and significantly reduce the risk of major cardiovascular events like heart attacks and strokes. Based on this proven ability to treat a key disease of aging, its role is now expanding into the field of healthspan optimization. By targeting cardiovascular risk through its triglyceride-lowering and anti-inflammatory effects, the intervention aims to extend the period of healthy life by mitigating a primary driver of age-related mortality and disability.

Purpose

A purified omega-3 fatty acid for reducing cardiovascular events.

Card Summary

A prescription-strength, purified EPA omega-3 fatty acid clinically proven to reduce cardiovascular events in high-risk individuals by lowering triglycerides and inflammation.

Drug Class

omega-3-fatty-acids

Drugs In Class

Empty Array

Impact

Score:
7.5
Justification:
Proven to significantly reduce major adverse cardiovascular events in high-risk individuals.

Evidence

Grade:
A
Score:
9.5
Justification:
Large, high-quality human RCTs (REDUCE-IT) show significant cardiovascular event reduction.

Safety

Score:
5.2
Justification:
Increased risk of atrial fibrillation and bleeding events requires medical supervision.

Flags

  • Increased risk of atrial fibrillation or atrial flutter requiring hospitalization was observed in clinical trials.
  • Associated with an increased risk of bleeding events, use with caution if on other anticoagulant/antiplatelet drugs.
  • Requires a prescription and is indicated for specific patient populations with elevated triglycerides and cardiovascular risk.
  • Use with caution in patients with a known hypersensitivity to fish or shellfish.

Verdict

A powerful, evidence-backed tool for cardiovascular risk reduction in the right patient.

Created

2026-04-27T00:54:15.936499Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:
oral
Scope:
  • systemic

Indication

Focus:
  • disease_treatment
  • healthspan
Description:
To reduce the risk of cardiovascular events in adults with elevated triglyceride levels and either established cardiovascular disease or diabetes mellitus. | Icosapent ethyl is a prescription, highly purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA). Its primary mechanism involves reducing triglyceride levels, but it also exerts anti-infl...

Typical Protocol

  • Take 2 grams twice daily with food for a total of 4 grams per day.